Vanguard Capital Management
CYCN icon

Vanguard Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

Vanguard Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Buy
30,915
+14,778
+92% +$48K ﹤0.01% 3872
2026
Q1 		$24.8K Buy
+16,137
New +$23K ﹤0.01% 3968

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $140M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management's CYCN Position: Q2 2026 in Review

Vanguard Capital Management increased its Cyclerion Therapeutics (CYCN) stake by 92% in Q2 2026, buying an estimated $48K and bringing the position to 30,915 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #3872.

Vanguard Capital Management first reported a position in CYCN in Q1 2026 and has held it in 2 quarters since. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • Vanguard Capital Management held 30,915 shares of Cyclerion Therapeutics worth $105K as of Q2 2026.
  • Vanguard Capital Management bought 14,778 Cyclerion Therapeutics shares in Q2 2026, an estimated $48K.
  • Cyclerion Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3872 holding.
  • Vanguard Capital Management first reported a position in Cyclerion Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.